The rationale for this project is given by the fact that the pharmaceutical industry is currently undergoing a significant change in strategy in preclinical drug development. Relevant advances are being made in the field of genome analysis with the onset of gene chip technologies permitting high throughput investigations and the use of miniature sample quantities. The same is happening for protease analysis and mass- spectrometry. We want to develop the "missing link" in high throughput testing: A highly controlled high-throughput bioreactor based on the use of engineered miniature in vitro tissue analogues. This will lead to the establishment of a firm correlation between genome, protease and catalytic expressions or biochemical function resulting in a complementary and more predictive picture of drug action.
Funding SchemeCSC - Cost-sharing contracts